Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer TranscriptSeeking Alpha · 1 day ago
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response RateMarketBeat · 1 day ago
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?Benzinga · 1 day ago
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer DrugInvestors Business Daily · 2 days ago
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development StrategyGlobeNewsWire · 2 days ago
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026GlobeNewsWire · Oct 16, 2026Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.32 | -$0.37 | Miss |
| May 13, 2026 | -$0.31 | -$0.32 | Miss |
| Mar 5, 2026 | -$0.31 | -$0.29 | Beat |
| Nov 4, 2025 | $0.01 | $0.13 | Beat |
| Aug 5, 2025 | -$0.35 | -$0.35 | Beat |
| May 12, 2025 | -$0.34 | -$0.36 | Miss |